Mounjaro® (tirzepatide) is a prescription injectable medication manufactured by Eli Lilly. It is a dual GIP and GLP-1 receptor agonist used along with diet and exercise to improve blood sugar control in adults and eligible pediatric patients with type 2 diabetes.
Tirzepatide may also reduce appetite and food intake and can result in weight loss. However, Mounjaro® is not FDA-approved specifically for weight loss. The tirzepatide brand FDA-approved for chronic weight management is Zepbound®, for eligible patients.
Mounjaro is administered once weekly and is available in several strengths. (accessdata.fda.gov)
Prescription use only. Use only under the direction of a qualified healthcare professional.
Mounjaro® is administered as a subcutaneous injection once weekly, at any time of day, with or without meals. Injection sites include the abdomen or thigh; another person may administer the injection in the back of the upper arm. Injection sites should be rotated.
The FDA-approved dosing schedule starts at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. If additional glycemic control is needed, the dose may be increased in 2.5 mg increments after at least 4 weeks at the current dose. The maximum adult dose is 15 mg once weekly. The appropriate dose must be determined by the prescribing healthcare professional. (accessdata.fda.gov)
A 2-pen pack: Each single-dose pen is intended for one weekly injection. Therefore, a 2-pen pack generally represents 2 weekly doses, not a full 1-month supply.
Mounjaro is intended as an ongoing prescription treatment rather than a short-term medication with a fixed duration.
While taking tirzepatide as prescribed, patients may experience ongoing effects on blood glucose control and body weight. If treatment is stopped, the medication's effects diminish, and weight regain may occur in people using tirzepatide for weight management.
For chronic weight management, Zepbound® (tirzepatide) is the FDA-approved tirzepatide product. Long-term treatment decisions should be made with a qualified healthcare professional based on the patient's health and treatment goals.
Mounjaro® (tirzepatide) is a prescription injectable medication manufactured by Eli Lilly. It is a dual GIP and GLP-1 receptor agonist used along with diet and exercise to improve blood sugar control in adults and eligible pediatric patients with type 2 diabetes.
Tirzepatide may also reduce appetite and food intake and can result in weight loss. However, Mounjaro® is not FDA-approved specifically for weight loss. The tirzepatide brand FDA-approved for chronic weight management is Zepbound®, for eligible patients.
Mounjaro is administered once weekly and is available in several strengths. (accessdata.fda.gov)
Prescription use only. Use only under the direction of a qualified healthcare professional.
Mounjaro® is administered as a subcutaneous injection once weekly, at any time of day, with or without meals. Injection sites include the abdomen or thigh; another person may administer the injection in the back of the upper arm. Injection sites should be rotated.
The FDA-approved dosing schedule starts at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. If additional glycemic control is needed, the dose may be increased in 2.5 mg increments after at least 4 weeks at the current dose. The maximum adult dose is 15 mg once weekly. The appropriate dose must be determined by the prescribing healthcare professional. (accessdata.fda.gov)
A 2-pen pack: Each single-dose pen is intended for one weekly injection. Therefore, a 2-pen pack generally represents 2 weekly doses, not a full 1-month supply.
Mounjaro is intended as an ongoing prescription treatment rather than a short-term medication with a fixed duration.
While taking tirzepatide as prescribed, patients may experience ongoing effects on blood glucose control and body weight. If treatment is stopped, the medication's effects diminish, and weight regain may occur in people using tirzepatide for weight management.
For chronic weight management, Zepbound® (tirzepatide) is the FDA-approved tirzepatide product. Long-term treatment decisions should be made with a qualified healthcare professional based on the patient's health and treatment goals.
